23
Palliative Management of Dyspnea Katherine Clark Clinical Associate Professor Calvary Mater Newcastle Hunter New England Health

Palliative Management of Dyspnea Katherine Clark Clinical Associate Professor Calvary Mater Newcastle Hunter New England Health

Embed Size (px)

Citation preview

Page 1: Palliative Management of Dyspnea Katherine Clark Clinical Associate Professor Calvary Mater Newcastle Hunter New England Health

Palliative Management of Dyspnea

Katherine ClarkClinical Associate ProfessorCalvary Mater NewcastleHunter New England Health

Page 2: Palliative Management of Dyspnea Katherine Clark Clinical Associate Professor Calvary Mater Newcastle Hunter New England Health

Contents

• Dyspnea defined

• Epidemiology of dyspnea in palliative care?

• The experience of dyspnea

• Anxiety and dyspnea

• Causes of dyspnea

• Palliation of dyspnea

Page 3: Palliative Management of Dyspnea Katherine Clark Clinical Associate Professor Calvary Mater Newcastle Hunter New England Health

Dyspnea defined

• Dyspnea is an uncomfortable sensation or awareness of breathing.

• A complex experience of mind and body that is likely to progress with disease severity.

• Significant correlation with impaired QoL and poor survival.

Page 4: Palliative Management of Dyspnea Katherine Clark Clinical Associate Professor Calvary Mater Newcastle Hunter New England Health

Prevalence of dyspnea in cancer

• Dyspnea is a common and distressing symptom experienced by patients with advanced cancer, occurring in 19–51% of patients.

• Higher incidences are reported towards the end of life with dyspnea defined as a poor prognostic indicator.

Page 5: Palliative Management of Dyspnea Katherine Clark Clinical Associate Professor Calvary Mater Newcastle Hunter New England Health

Prevalence of dyspnea?

• The prevalence of dyspnea varies with the primary tumor site;

• It occurs in 46% of patients with advanced lung cancer, but in only 7% of those with advanced gastric cancer.

• Of those with the symptom, 60–80% rate it as clinically important.

Page 6: Palliative Management of Dyspnea Katherine Clark Clinical Associate Professor Calvary Mater Newcastle Hunter New England Health

Dyspnea in non-malignant disease

• For patients with COPD, intractable breathlessness develops late in the course of the disease, gradually increasing in severity over a period of years in the majority of people.

• There is a long pre-clinical phase when patients may not have any respiratory symptoms at all, although lung damage exists.

Page 7: Palliative Management of Dyspnea Katherine Clark Clinical Associate Professor Calvary Mater Newcastle Hunter New England Health

Dyspnea in non-malignant disease

• There is then a protracted period of gradual decline punctuated by severe exacerbations, which may be life-threatening and require inpatient management.

• Breathlessness tends to be associated predictably with exertion, until the end of life when it may be present at rest.

Page 8: Palliative Management of Dyspnea Katherine Clark Clinical Associate Professor Calvary Mater Newcastle Hunter New England Health

The personal experience of dyspnea

• Many studies have confirmed that breathlessness is a particularly distressing symptom for patients and their families.

• A qualitative study that investigated the experience of patients with cancer or COPD and carers, found high levels of anxiety, particularly at night.

Page 9: Palliative Management of Dyspnea Katherine Clark Clinical Associate Professor Calvary Mater Newcastle Hunter New England Health

Personal experience’s of dyspnea

• This anxiety was reported in both relatives and patients.

• Patients reported thinking "Will I get much shorter of breath? Can I manage it? Is something terrible going to happen? Will I suffocate to death?"

• Carers report a sense of helplessness and fear.

Page 10: Palliative Management of Dyspnea Katherine Clark Clinical Associate Professor Calvary Mater Newcastle Hunter New England Health

Anxiety and dyspnea

• There is uncertainty about the contribution of anxiety in breathlessness;

• The incidence of anxiety in patients with the diagnosis of any cancer greatly exceeds that in the normal population.

• Neuroimaging and psychophysical studies are now helping to assess the contribution of distress and anxiety to the genesis of breathlessness;

Page 11: Palliative Management of Dyspnea Katherine Clark Clinical Associate Professor Calvary Mater Newcastle Hunter New England Health

Pathophysiology of dyspnea

• The neurophysiology of dyspnea is complex and poorly understood, but it is clear that there is some similarity with the genesis of intractable pain.

• Both pain and dyspnea are somatopsychic experiences arising from multiple receptors integrated at various levels in the central nervous system and therefore susceptible to modulation by both physiological and psychological influences.

Page 12: Palliative Management of Dyspnea Katherine Clark Clinical Associate Professor Calvary Mater Newcastle Hunter New England Health

Pathophysiology of dyspnea

Page 13: Palliative Management of Dyspnea Katherine Clark Clinical Associate Professor Calvary Mater Newcastle Hunter New England Health

Some causes of dyspnea in palliative care

• Direct– Tumour mass, pleural and pericardial effusion,

phrenic nerve paralysis, vena caval obstruction, carcinomatosis, airway obstruction.

• Indirect– Anaemia, radiotherapy, infection, cachexia,

pulmonary embolus. • Co-morbidity

– Airways, cardiac and renal diseases, depression, anxiety.

Page 14: Palliative Management of Dyspnea Katherine Clark Clinical Associate Professor Calvary Mater Newcastle Hunter New England Health

Causes of dyspnea

• Dyspnea in advanced cancer is usually multifactorial:

• Although reversible causes should be sought, a significant proportion of the underlying causes are irreversible.

• The burden/benefit of the intervention for the patient needs to be evaluated by them.

• If extra visits to hospital are required, will the relief provided exceed the exhaustion incurred?

Page 15: Palliative Management of Dyspnea Katherine Clark Clinical Associate Professor Calvary Mater Newcastle Hunter New England Health

Palliating Dyspnea

Page 16: Palliative Management of Dyspnea Katherine Clark Clinical Associate Professor Calvary Mater Newcastle Hunter New England Health

Non-pharmacological approaches

• Good evidence to support behavioural and nursing interventions to manage dyspnoea.

• Emotional and cognitive aspects which respond well to:– Relaxation,– Breathing exercises, – Psychological support,– Positioning,– Moving air over the face.

Page 17: Palliative Management of Dyspnea Katherine Clark Clinical Associate Professor Calvary Mater Newcastle Hunter New England Health

Pharmacological approaches

• Opioids,

• Oxygen,

• Antidepressants,

• Anxiolytics,

• (Corticosteroids),

• (Bronchodilators).

Page 18: Palliative Management of Dyspnea Katherine Clark Clinical Associate Professor Calvary Mater Newcastle Hunter New England Health

Opioids• Opioids are the most effective pharmacological

agents for the relief of dyspnoea. • High level evidence supports:

– Low dose of oral morphine for opioid naïve (10-20mg/24hours),

– Increase dose by 25% patients taking morphine for other reasons.

– No role yet confirmed for nebulised morphine.

Page 19: Palliative Management of Dyspnea Katherine Clark Clinical Associate Professor Calvary Mater Newcastle Hunter New England Health

Oxygen

• Regardless of whether people are hypoxic or non-hypoxic, O2 has little role to play in the management of the symptom of dyspnea;

• In hypoxic people, O2 confers a survival benefit.

• In non-hypoxic people, recent RCT supports the null hypothesis that very few people will gain any benefit from supplemental O2.

Page 20: Palliative Management of Dyspnea Katherine Clark Clinical Associate Professor Calvary Mater Newcastle Hunter New England Health

Antidepressants and Anxiolytics

• There is some evidence which supports the use of antidepressants in the palliation of dyspnea;

• But less evidence for the use of benzodiazepines;

• However, best clinical guidelines continue to recommend agents such as lorazepam or clonazepam be readily available.

Page 21: Palliative Management of Dyspnea Katherine Clark Clinical Associate Professor Calvary Mater Newcastle Hunter New England Health

An evidence based algorithm to palliate dyspnea?

Page 22: Palliative Management of Dyspnea Katherine Clark Clinical Associate Professor Calvary Mater Newcastle Hunter New England Health

Increasing shortness of breath in a person with life-limiting illness and estimated prognosis of less then 3

months

Reversible causes of dyspnoea sought?

Sa02 <90% on room air

Sa02 >90% on room air

Request for O2 Multidisciplinary referrals:Physio

Breathing control exercisesRelaxation exercisesWalking frameChest physio

OTPhysical aidsActivity pacing

Social workSocial support/financesMeditation/relaxation

Pastoral CareMedical Officer

Low dose morphine Screen for depression and anxiety

NursingAdvice re positioning Moving air

Ongoing dyspnoea?Referral to palliative care

Trial of O2

Page 23: Palliative Management of Dyspnea Katherine Clark Clinical Associate Professor Calvary Mater Newcastle Hunter New England Health

Questions?